These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11464976)

  • 1. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.
    Schneeweiss A; Goerner R; Hensel MA; Lauschner I; Sinn P; Kaul S; Egerer G; Beldermann F; Geberth M; Solomayer E; Grischke EM; Haas R; Ho AD; Bastert G
    Biol Blood Marrow Transplant; 2001; 7(6):332-42. PubMed ID: 11464976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.
    Hensel M; Schneeweiss A; Sinn HP; Egerer G; Solomayer E; Haas R; Bastert G; Ho AD
    Int J Cancer; 2002 Jul; 100(3):290-6. PubMed ID: 12115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation.
    Nieto Y; Cagnoni PJ; Nawaz S; Shpall EJ; Yerushalmi R; Cook B; Russell P; McDermit J; Murphy J; Bearman SI; Jones RB
    J Clin Oncol; 2000 May; 18(10):2070-80. PubMed ID: 10811672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
    Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
    Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.
    Schneeweiss A; Diel I; Hensel M; Kaul S; Sinn HP; Unnebrink K; Rudlowski C; Lauschner I; Schuetz F; Egerer G; Haas R; Ho AD; Bastert G
    Ann Oncol; 2004 Nov; 15(11):1627-32. PubMed ID: 15520063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
    N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
    Somlo G; Doroshow JH; Forman SJ; Odom-Maryon T; Lee J; Chow W; Hamasaki V; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Simpson J; Molina A
    J Clin Oncol; 1997 Aug; 15(8):2882-93. PubMed ID: 9256132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
    Steenbruggen TG; Steggink LC; Seynaeve CM; van der Hoeven JJM; Hooning MJ; Jager A; Konings IR; Kroep JR; Smit WM; Tjan-Heijnen VCG; van der Wall E; Bins AD; Linn SC; Schaapveld M; Jacobse JN; van Leeuwen FE; Schröder CP; van Tinteren H; de Vries EGE; Sonke GS; Gietema JA
    JAMA Oncol; 2020 Apr; 6(4):528-534. PubMed ID: 31999296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
    Schrama JG; Faneyte IF; Schornagel JH; Baars JW; Peterse JL; van de Vijver MJ; Dalesio O; van Tinteren H; Rutgers EJ; Richelt DJ; Rodenhuis S
    Ann Oncol; 2002 May; 13(5):689-98. PubMed ID: 12075736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
    Schumacher M; Bastert G; Bojar H; Hübner K; Olschewski M; Sauerbrei W; Schmoor C; Beyerle C; Neumann RL; Rauschecker HF
    J Clin Oncol; 1994 Oct; 12(10):2086-93. PubMed ID: 7931478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.
    García-Carbonero R; Hidalgo M; Paz-Ares L; Calzas J; Gómez H; Guerra JA; Hitt R; Hornedo J; Colomer R; Cortés-Funes H
    J Clin Oncol; 1997 Oct; 15(10):3178-84. PubMed ID: 9336353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
    Ménard S; Valagussa P; Pilotti S; Gianni L; Biganzoli E; Boracchi P; Tomasic G; Casalini P; Marubini E; Colnaghi MI; Cascinelli N; Bonadonna G
    J Clin Oncol; 2001 Jan; 19(2):329-35. PubMed ID: 11208823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.